Zacks: Analysts Expect Tandem Diabetes Care Inc (NASDAQ:TNDM) Will Announce Earnings of -$0.17 Per Share

Wall Street analysts forecast that Tandem Diabetes Care Inc (NASDAQ:TNDM) will report earnings of ($0.17) per share for the current quarter, Zacks Investment Research reports. Six analysts have made estimates for Tandem Diabetes Care’s earnings, with the highest EPS estimate coming in at ($0.10) and the lowest estimate coming in at ($0.27). Tandem Diabetes Care posted earnings per share of ($0.18) during the same quarter last year, which indicates a positive year over year growth rate of 5.6%. The business is expected to issue its next quarterly earnings report on Tuesday, May 5th.

According to Zacks, analysts expect that Tandem Diabetes Care will report full year earnings of ($0.03) per share for the current year, with EPS estimates ranging from ($0.29) to $0.14. For the next financial year, analysts anticipate that the business will post earnings of $0.34 per share, with EPS estimates ranging from $0.17 to $0.73. Zacks’ earnings per share averages are an average based on a survey of research firms that follow Tandem Diabetes Care.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its quarterly earnings results on Monday, February 24th. The medical device company reported $0.04 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.07. Tandem Diabetes Care had a negative return on equity of 8.99% and a negative net margin of 6.83%. The firm had revenue of $108.40 million for the quarter, compared to analyst estimates of $109.22 million. During the same period in the previous year, the firm earned $0.02 earnings per share. Tandem Diabetes Care’s quarterly revenue was up 42.3% on a year-over-year basis.

Several research analysts have weighed in on the company. Oppenheimer upped their target price on Tandem Diabetes Care from to in a research report on Tuesday, February 25th. Robert W. Baird lowered Tandem Diabetes Care from an “outperform” rating to a “neutral” rating and upped their target price for the stock from $71.00 to $75.00 in a research report on Tuesday, February 4th. Cowen reaffirmed an “outperform” rating and issued a $90.00 target price (up from $85.00) on shares of Tandem Diabetes Care in a research report on Tuesday, February 25th. Guggenheim lowered Tandem Diabetes Care from a “buy” rating to a “neutral” rating in a research report on Monday. Finally, Craig Hallum upped their target price on Tandem Diabetes Care from $92.00 to $108.00 and gave the stock a “buy” rating in a research report on Tuesday, February 25th. Five research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $84.67.

In other news, CFO Leigh Vosseller sold 10,000 shares of the stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $75.93, for a total transaction of $759,300.00. Following the transaction, the chief financial officer now owns 12,882 shares of the company’s stock, valued at approximately $978,130.26. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Dick Allen sold 2,979 shares of the stock in a transaction dated Wednesday, February 26th. The shares were sold at an average price of $78.82, for a total value of $234,804.78. The disclosure for this sale can be found here. In the last three months, insiders have sold 102,295 shares of company stock worth $7,745,966. 6.90% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the company. CWM LLC boosted its stake in Tandem Diabetes Care by 393.5% during the 4th quarter. CWM LLC now owns 528 shares of the medical device company’s stock valued at $31,000 after purchasing an additional 421 shares during the period. TRUE Private Wealth Advisors bought a new stake in Tandem Diabetes Care during the 4th quarter valued at approximately $45,000. Sowell Financial Services LLC bought a new stake in Tandem Diabetes Care during the 4th quarter valued at approximately $54,000. US Bancorp DE boosted its stake in Tandem Diabetes Care by 101.0% during the 4th quarter. US Bancorp DE now owns 1,164 shares of the medical device company’s stock valued at $70,000 after purchasing an additional 585 shares during the period. Finally, Schroder Investment Management Group bought a new stake in Tandem Diabetes Care during the 4th quarter valued at approximately $141,000. 90.92% of the stock is currently owned by institutional investors and hedge funds.

TNDM stock traded up $7.66 during mid-day trading on Monday, hitting $65.16. The stock had a trading volume of 1,947,100 shares, compared to its average volume of 1,613,822. The company has a current ratio of 2.78, a quick ratio of 2.28 and a debt-to-equity ratio of 0.07. Tandem Diabetes Care has a 1-year low of $43.69 and a 1-year high of $91.65. The company has a fifty day moving average of $72.09 and a 200 day moving average of $65.59. The stock has a market capitalization of $3.30 billion, a price-to-earnings ratio of -135.75 and a beta of 0.20.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

Recommended Story: What is the NASDAQ Stock Market?

Get a free copy of the Zacks research report on Tandem Diabetes Care (TNDM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.